Evaluation of Reader Training Processes

Avid Pharmaceuticals

Status and phase: Completed; Phase 4

Conditions: Alzheimer's Disease

Treatments: Drug: florbetapir F 18

Study type: Interventional

Funder types: Industry

Identifiers

NCT02051790

18F-AV-45-RTP01

Details and patient eligibility

About

This study is designed to evaluate the agreement between florbetapir F 18 scan interpretation in the clinic and by expert readers.

Enrollment: 241 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Scan obtained for clinical reasons

Exclusion criteria

• None

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: Single Blind

---

241 participants in 1 patient group

Clinical Practice Scans

Experimental group

Description:

Approximately 250 florbetapir F 18 scans and final scan reports interpreted in a clinical setting will be collected from physicians across the country. These results will then be compared to expert panel interpretations for the same scans.

Treatment:

Drug: florbetapir F 18